The results showed that knockdown of KRT17 or treatment with cisplatin significantly inhibited tumor growth, while cisplatin treatment in KRT17-knockdown xenografts elicited significant synergistic inhibition (Fig. 7B, C). The gene discussed is KRT17; the disease is neoplasm.